Publications by authors named "Guixue Yu"

Claim this Profile
R
Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.
Bruce A Ellsworth, Philip M Sher, Ximao Wu, Gang Wu, Richard B Sulsky, Guixue Yu

J Med Chem· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insight into the mechanism of inactivation of ribonucleotide reductase by gemcitabine 5'-diphosphate in the presence or absence of reductant.
Erin Artin, Jun Wang, Gregory J S Lohman, Kenichi Yokoyama, Guixue Yu

Biochemistry· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A selective small molecule agonist of the melanocortin-1 receptor inhibits lipopolysaccharide-induced cytokine accumulation and leukocyte infiltration in mice.
Liya Kang, Kim W McIntyre, Kathleen M Gillooly, Yifan Yang, John Haycock, Guixue Yu

J Leukoc Biol· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
beta-alanine dipeptides as MC4R agonists.
Réjean Ruel, Timothy F Herpin, Lawrence Iben, Guanglin Luo, Alain Martel, Guixue Yu

Bioorg Med Chem Lett· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-steady-state and steady-state kinetic analysis of E. coli class I ribonucleotide reductase.
Jie Ge, Guixue Yu, Mark A Ator, JoAnne Stubbe

Biochemistry· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of tyrosine-based potent and selective melanocortin-1 receptor small-molecule agonists with anti-inflammatory properties.
Timothy F Herpin, Guixue Yu, Kenneth E Carlson, George C Morton, Ximao Wu

J Med Chem· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.
Guixue Yu, Helen Mason, Ximao Wu, Jian Wang, Saeho Chong

J Med Chem· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis